{
    "id": "New-v26-9c3a8b2d-1e4f-4a5b-8c7d-6e9f8a7b6c5d",
    "type": "clozeDropdown",
    "stem": "The nurse is caring for a postpartum client at risk for hemorrhage. Based on the clinical data, complete the following sentence. The nurse should anticipate administering [dropdown1] to manage the client's [dropdown2], while closely monitoring for [dropdown3] as a potential adverse effect.",
    "dropdowns": [
        {
            "id": "dropdown1",
            "options": [
                {
                    "id": "opt1_1",
                    "text": "Methylergonovine"
                },
                {
                    "id": "opt1_2",
                    "text": "Oxytocin"
                },
                {
                    "id": "opt1_3",
                    "text": "Misoprostol"
                },
                {
                    "id": "opt1_4",
                    "text": "Carboprost"
                }
            ],
            "correctOptionId": "opt1_1"
        },
        {
            "id": "dropdown2",
            "options": [
                {
                    "id": "opt2_1",
                    "text": "uterine atony"
                },
                {
                    "id": "opt2_2",
                    "text": "hypertension"
                },
                {
                    "id": "opt2_3",
                    "text": "pain"
                },
                {
                    "id": "opt2_4",
                    "text": "infection"
                }
            ],
            "correctOptionId": "opt2_1"
        },
        {
            "id": "dropdown3",
            "options": [
                {
                    "id": "opt3_1",
                    "text": "signs of ergot toxicity"
                },
                {
                    "id": "opt3_2",
                    "text": "hypotension"
                },
                {
                    "id": "opt3_3",
                    "text": "decreased urine output"
                },
                {
                    "id": "opt3_4",
                    "text": "increased pain"
                }
            ],
            "correctOptionId": "opt3_1"
        }
    ],
    "itemContext": {
        "patient": {
            "name": "Maria Rodriguez",
            "age": "32 years",
            "sex": "Female",
            "pronouns": "she/her",
            "allergies": [
                "Sulfa Drugs"
            ]
        },
        "tabs": [
            {
                "id": "nurses_notes",
                "title": "Clinical Feed (Nurses' Notes)",
                "content": [
                    {
                        "timestamp": "Day 1, 03:30",
                        "noteType": "Admission Note",
                        "author": "J. Doe, RN",
                        "text": "S: Client admitted to postpartum unit following vaginal delivery of a viable infant at 03:00. Estimated blood loss 600 mL. Oxytocin infusing. Client reports feeling tired but stable.\nB: 32-year-old G2P2 with a history of preeclampsia this pregnancy, managed with labetalol. Labor was prolonged, with a second stage lasting 3 hours. Received magnesium sulfate for seizure prophylaxis during labor. Client lives in a rural area, approximately 90 minutes from the hospital, which may impact follow-up care access.\nA: Vital signs stable post-delivery. Fundus firm at umbilicus. Lochia rubra moderate. Bonding with infant at bedside.\nR: Continue postpartum monitoring per protocol. Encourage rest and hydration. Monitor vital signs, fundal tone, and bleeding closely due to increased risk for PPH. Continue oxytocin infusion as ordered."
                    },
                    {
                        "timestamp": "Day 1, 08:00",
                        "noteType": "Progress Note",
                        "author": "J. Doe, RN",
                        "text": "S: Client used call light to report feeling 'weak and dizzy.' Denies significant pain, rating it 2/10.\nB: Client is 5 hours postpartum. Risk factors for PPH include prolonged labor, magnesium sulfate administration, and history of preeclampsia. Oxytocin has been infusing since delivery. Morning labetalol dose was held by provider.\nA: BP 150/95 mmHg, HR 110 bpm, RR 20/min, SpO2 98% on room air. Uterine fundus is boggy, located 2 cm above the umbilicus, and deviated to the right. Moderate lochia rubra noted on peripad with several small clots. Skin is cool and clammy. Client is alert and oriented.\nR: Initiated vigorous fundal massage. Paged provider to report findings and request orders for a second-line uterotonic. Anticipate order for methylergonovine. Continue to monitor vital signs and bleeding every 15 minutes."
                    }
                ]
            },
            {
                "id": "vitals_telemetry",
                "title": "Vitals & Telemetry",
                "content": [
                    {
                        "Time": "07:00",
                        "HR": "98",
                        "BP": "155/98",
                        "MAP": "117",
                        "RR": "18",
                        "SpO2": "99% on room air",
                        "Temp": "98.8°F (37.1°C)"
                    },
                    {
                        "Time": "07:30",
                        "HR": "105",
                        "BP": "152/96",
                        "MAP": "115",
                        "RR": "19",
                        "SpO2": "98% on room air",
                        "Temp": "98.8°F (37.1°C)"
                    },
                    {
                        "Time": "08:00",
                        "HR": "110",
                        "BP": "150/95",
                        "MAP": "113",
                        "RR": "20",
                        "SpO2": "98% on room air",
                        "Temp": "98.9°F (37.2°C)"
                    }
                ]
            },
            {
                "id": "lab_diagnostics",
                "title": "Lab Diagnostics",
                "content": [
                    {
                        "Test": "Hemoglobin",
                        "Result": "9.8",
                        "Unit": "g/dL",
                        "Reference Range": "12.0-15.5",
                        "Status": "Low"
                    },
                    {
                        "Test": "Hematocrit",
                        "Result": "29",
                        "Unit": "%",
                        "Reference Range": "34.9-44.5",
                        "Status": "Low"
                    },
                    {
                        "Test": "Platelets",
                        "Result": "130",
                        "Unit": "x10³/mcL",
                        "Reference Range": "150-450",
                        "Status": "Low"
                    },
                    {
                        "Test": "Prothrombin Time (PT)",
                        "Result": "12.5",
                        "Unit": "seconds",
                        "Reference Range": "11-13.5",
                        "Status": "Normal"
                    },
                    {
                        "Test": "Urinalysis, Protein",
                        "Result": "1+",
                        "Unit": "",
                        "Reference Range": "Negative",
                        "Status": "High"
                    }
                ]
            },
            {
                "id": "physical_exam",
                "title": "Physical Exam",
                "content": [
                    {
                        "System": "Cardiovascular",
                        "Findings": "Tachycardia with regular rhythm. S1, S2 audible. Capillary refill 3 seconds. Pulses 2+ peripherally. Skin cool, clammy."
                    },
                    {
                        "System": "Respiratory",
                        "Findings": "Lungs clear to auscultation bilaterally. Respirations unlabored."
                    },
                    {
                        "System": "Neurological",
                        "Findings": "Alert and oriented x4. Reports feeling weak and dizzy. No headache or visual changes."
                    },
                    {
                        "System": "Gastrointestinal/Genitourinary",
                        "Findings": "Abdomen soft. Uterus: Boggy on palpation, located 2 cm above umbilicus, deviated to the right. Lochia: Rubra, moderate flow, several small clots noted. Foley catheter in place, draining clear yellow urine."
                    }
                ]
            },
            {
                "id": "radiology",
                "title": "Radiology (Imaging & Diagnostics)",
                "content": "No imaging studies on file."
            },
            {
                "id": "care_plan",
                "title": "Care Plan (Orders & Interventions)",
                "content": [
                    {
                        "Order Date/Time": "Day 1, 03:00",
                        "Action": "Oxytocin 20 units in 1000 mL Lactated Ringers IV",
                        "Frequency/Status": "Continuous at 125 mL/hr"
                    },
                    {
                        "Order Date/Time": "Day 1, 03:00",
                        "Action": "Lactated Ringers IV",
                        "Frequency/Status": "Continuous at 125 mL/hr"
                    },
                    {
                        "Order Date/Time": "Day 1, 03:00",
                        "Action": "Methylergonovine 0.2 mg IM",
                        "Frequency/Status": "PRN x1 for boggy uterus"
                    },
                    {
                        "Order Date/Time": "Day 1, 07:00",
                        "Action": "Labetalol 200 mg PO BID",
                        "Frequency/Status": "Held this morning per provider"
                    }
                ]
            },
            {
                "id": "mar_console",
                "title": "MAR Console (Medications)",
                "content": [
                    {
                        "Medication": "Oxytocin IV Infusion",
                        "Dose": "20 units/1000 mL",
                        "Route": "IV",
                        "Frequency": "Continuous",
                        "Last Administered": "Day 1, 03:00 (Ongoing)"
                    },
                    {
                        "Medication": "Labetalol",
                        "Dose": "200 mg",
                        "Route": "PO",
                        "Frequency": "BID",
                        "Last Administered": "Yesterday, 19:00"
                    },
                    {
                        "Medication": "Methylergonovine",
                        "Dose": "0.2 mg",
                        "Route": "IM",
                        "Frequency": "PRN",
                        "Last Administered": "N/A"
                    }
                ]
            }
        ]
    },
    "rationale": {
        "correct": "The client's clinical presentation—boggy and deviated uterus, increasing tachycardia, and history of prolonged labor with magnesium sulfate—are classic signs of postpartum hemorrhage (PPH) due to uterine atony. The first-line uterotonic, oxytocin, is already infusing without effect. Therefore, a second-line agent is required. Methylergonovine is an ergot alkaloid that causes potent uterine contractions. It is the appropriate next step to manage uterine atony. Because it is a vasoconstrictor and the client has preeclampsia, the nurse must vigilantly monitor for adverse effects, specifically signs of ergot toxicity, which include a severe hypertensive crisis, chest pain, and seizures.",
        "answerBreakdown": [
            {
                "optionId": "opt1_1",
                "content": "Correct. Methylergonovine is a potent second-line uterotonic agent used to control PPH when oxytocin is ineffective. It acts directly on the uterine smooth muscle to produce firm, sustained contractions."
            },
            {
                "optionId": "opt1_2",
                "content": "Incorrect. Oxytocin is already infusing and has failed to resolve the uterine atony, as evidenced by the persistently boggy fundus. Continuing the same treatment without escalation is inappropriate."
            },
            {
                "optionId": "opt1_3",
                "content": "Incorrect. Misoprostol is a prostaglandin analog that can be used for PPH, but methylergonovine is often the preferred next agent after oxytocin, especially when a rapid-acting IM medication is desired."
            },
            {
                "optionId": "opt1_4",
                "content": "Incorrect. Carboprost is a potent uterotonic but is used with extreme caution in clients with hypertension due to its significant vasoconstrictive effects, making it a higher-risk choice for this client with preeclampsia."
            },
            {
                "optionId": "opt2_1",
                "content": "Correct. A boggy, enlarged, and deviated uterus is the hallmark sign of uterine atony, which is the failure of the uterus to contract adequately after birth and the leading cause of PPH."
            },
            {
                "optionId": "opt2_2",
                "content": "Incorrect. While the client is hypertensive, the medication is administered to treat uterine atony, not hypertension. The hypertension is a critical comorbidity that increases the risk of the intervention."
            },
            {
                "optionId": "opt2_3",
                "content": "Incorrect. The client's pain level is low (2/10). The primary clinical problem is hemorrhage, not pain."
            },
            {
                "optionId": "opt2_4",
                "content": "Incorrect. There are no clinical indicators of infection, such as fever or foul-smelling lochia. The client's presentation is acute and hemorrhagic."
            },
            {
                "optionId": "opt3_1",
                "content": "Correct. Methylergonovine is an ergot alkaloid. The most severe adverse effects are related to its vasoconstrictive properties, leading to ergotism or ergot toxicity, characterized by severe hypertension, headache, chest pain, and potential seizures."
            },
            {
                "optionId": "opt3_2",
                "content": "Incorrect. The primary risk of methylergonovine is severe hypertension, not hypotension. Hypotension would be a sign of worsening hemorrhagic shock, not a medication side effect."
            },
            {
                "optionId": "opt3_3",
                "content": "Incorrect. While monitoring urine output is essential for assessing renal perfusion and overall fluid status in a hemorrhaging client, it is not a specific adverse effect of methylergonovine."
            },
            {
                "optionId": "opt3_4",
                "content": "Incorrect. The medication causes uterine contractions, which can be painful. However, this is an expected therapeutic effect. Monitoring for life-threatening toxicity is a higher priority than monitoring for expected cramping."
            }
        ],
        "clinicalPearls": [
            "Methylergonovine is typically contraindicated in clients with hypertension or preeclampsia. However, in a life-threatening PPH, a provider may determine the benefit of controlling hemorrhage outweighs the risk of exacerbating hypertension.",
            "A boggy uterus that is deviated from the midline (usually to the right) strongly suggests uterine atony compounded by a full bladder, which displaces the uterus and prevents effective contraction. Assisting the client to void or catheterization is a key intervention.",
            "Magnesium sulfate, used for seizure prophylaxis in preeclampsia, is a smooth muscle relaxant. This action significantly increases the risk for uterine atony and subsequent postpartum hemorrhage."
        ],
        "questionTrap": "The primary trap is the client's hypertension, which is a known contraindication for methylergonovine. This may lead test-takers to incorrectly eliminate the correct medication without considering the risk-benefit analysis in a life-threatening hemorrhage where first-line therapy has failed.",
        "mnemonic": "The 4 T's of Postpartum Hemorrhage: Tone (uterine atony - the most common cause), Trauma (lacerations, hematoma, uterine rupture), Tissue (retained placental fragments), and Thrombin (coagulopathies).",
        "reviewUnits": [
            "Maternal/Newborn Nursing",
            "Pharmacology"
        ]
    },
    "scoring": {
        "method": "0/1",
        "maxPoints": 3
    },
    "pedagogy": {
        "bloomLevel": "Apply",
        "cjmmStep": "Generate Solutions",
        "nclexCategory": "Physiological Integrity"
    },
    "qualityMark": "NGN-2026-HI-FI",
    "healedAt": "2026-02-28T13:58:56.533Z"
}